ARCHIMEDlife News
Diagnostic Strategy for Females Suspected of Fabry Disease
18. February 2020
Fabry disease, an X-linked inherited lysosomal storage disorder, can be overlooked in heterozygous females due to random X-inactivation. In...
Read moreHemoglobinopathies and β-Thalassemia: Investigating High-Res Mass Spectrometry
18. February 2020
Early diagnosis of hemoglobin disorders and Thalassemias are become more important due to a high carrier frequency and ease...
Read more
amedes and ARCHIMEDlife – a new strong international alliance
17. January 2020
ARCHIMEDlife is very proud to announce the strategic alliance with amedes Holding GmbH, a leading provider in interdisciplinary and...
Read more
ARCHIMEDlife and Blueprint Genetics – partnership in North America
25. September 2019
Combining high-quality biochemical testing with innovative genetic testing forms a powerful tool for personalized medicine, clinical research and diagnostics...
Read more
SSIEM 2019 in Rotterdam
27. August 2019
Exciting! Our booth with a brand new look and novel, innovative portfolio of diagnostic tests and services. First time...
Read more
New cut-offs for lysosomal enzyme activities.
6. June 2019
We are happy to inform you that we have introduced a new diagnostic assay for the analysis of lysosomal...
Read more
TDM für Psychopharmaka: (in German)
26. February 2019
Quantitative Bestimmung von Psychopharmaka in Blut, Serum oder Plasma Modernste Analysetechnik mittels Klinischer Massenspektrometrie (exakt, sensitiv, schnell) Kompetente fachärztliche Auskunft...
Read more
Improving our ability to diagnose Hemoglobinopathies.
1. October 2018
Results of a prospective study using High-Resolution Mass Spectrometry. The goal of our study, in cooperation with the University...
Read more
First LEA assay launched
14. March 2018
LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses...
Read more